The CALYX trial is a phase 3, multicenter, randomized (1:1), double-blind, placebo-controlled, clinical study that has been designed to compare the efficacy and safety of leriglitazone with that of placebo in the treatment of cerebral adrenoleukodystrophy (cALD).

The NEXUS clinical trial is a phase 2, open-label clinical study that has been designed to assess the efficacy and safety of leriglitazone in male pediatric patients with early stage cerebral X-linked adrenoleukodystrophy (cALD).

The ADVANCE trial is a pivotal phase 2/3 randomized, double-blind, placebo-controlled, clinical study with an open-label extension that has been designed to assess the efficacy and safety of leriglitazone in male patients with adrenomyeloneuropathy (AMN).

The FRAMES trial is a phase 2 randomized, double-blind, placebo-controlled, clinical study that has been designed to assess the efficacy and safety of leriglitazone in patients with Friedreich's ataxia (FRDA). This study has been designed with input from EU and US clinical experts and patient advocacy groups.